Switch theme
Sign up to access all valuation multiples
iZafe Group AB is a pure Life-Science company engaged in the development of digital drug dispensing. The company conducts research, development and marketing of digital medical solutions and services for safer drug management at home. iZafe's drug robot Dosell is used to reduce the risk of incorrect medication at home, relieve public care, increase the patient's quality of life and create a safer environment for relatives. The customers consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe sells through well-established partners who already have long and deep customer relationships with the priority customer groups.
2008
12
Last FY Revenue $0.8M
Last FY EBITDA -$1.6M
$8.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, iZafe Group achieved revenue of $0.8M and an EBITDA of -$1.6M.
iZafe Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See iZafe Group valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.8M | XXX | XXX | XXX |
| Gross Profit | XXX | -$0.2M | XXX | XXX | XXX |
| Gross Margin | XXX | -21% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -194% | XXX | XXX | XXX |
| EBIT | XXX | -$2.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -262% | XXX | XXX | XXX |
| Net Profit | XXX | -$2.2M | XXX | XXX | XXX |
| Net Margin | XXX | -258% | XXX | XXX | XXX |
| Net Debt | XXX | $0.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 3, 2025, iZafe Group's stock price is SEK 0 (or $0).
iZafe Group has current market cap of SEK 76.0M (or $8.0M), and EV of SEK 80.4M (or $8.5M).
See iZafe Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.5M | $8.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 3, 2025, iZafe Group has market cap of $8.0M and EV of $8.5M.
iZafe Group's trades at 10.1x EV/Revenue multiple, and -5.2x EV/EBITDA.
Equity research analysts estimate iZafe Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
iZafe Group's P/E ratio is not available.
See valuation multiples for iZafe Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.0M | XXX | $8.0M | XXX | XXX | XXX |
| EV (current) | $8.5M | XXX | $8.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 10.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -5.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialiZafe Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
iZafe Group's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
iZafe Group's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for iZafe Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -194% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 242% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
iZafe Group acquired XXX companies to date.
Last acquisition by iZafe Group was XXXXXXXX, XXXXX XXXXX XXXXXX . iZafe Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was iZafe Group founded? | iZafe Group was founded in 2008. |
| Where is iZafe Group headquartered? | iZafe Group is headquartered in Sweden. |
| How many employees does iZafe Group have? | As of today, iZafe Group has 12 employees. |
| Is iZafe Group publicy listed? | Yes, iZafe Group is a public company listed on STO. |
| What is the stock symbol of iZafe Group? | iZafe Group trades under IZAFE B ticker. |
| When did iZafe Group go public? | iZafe Group went public in 2011. |
| Who are competitors of iZafe Group? | Similar companies to iZafe Group include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of iZafe Group? | iZafe Group's current market cap is $8.0M |
| Is iZafe Group profitable? | Yes, iZafe Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
